Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome;Relación entre el cociente triglicéridos/cHDL, índices de resistencia a la insulina y factores de riesgo cardiometabólico en mujeres con síndrome del ovario poliquístico

Endocrinologia y Nutricion

Volumn 56, Issue 2, 2009, Pages 59-65

  Roa Barrios, Marlene ^a   Arata Bellabarba, Gabriela ^a   Valeri, Lenin ^a   Velázquez Maldonado, Elsy ^a  

^a UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

Insulin resistance; Polycystic ovary syndrome; Triglycerides HDL c

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; ANTHROPOMETRY; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COMORBIDITY; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; DYSLIPIDEMIAS; ETHNIC GROUPS; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; TRIGLYCERIDES; VENEZUELA; YOUNG ADULT;

EID: 65449154000     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(09)70553-4     Document Type: Article

References (29)

1. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the south-eastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
2. Franks S. Polycystic ovary syndrome: A changing perspective. Clin Endocrinol 31 (1989) 87-120
3. Dunaif A., Segal K., Futterweit Q., and Dobransky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
4. Cho L.W., Randeva H.S., and Atkin S.L. Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag 3 (2007) 55-63
5. Reaven G. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care 14 (1991) 195-201
6. Ruotolo G., and Howard B. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 4 (2002) 494-500
7. Brunzell J.D., and Ayyobi A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 115 Suppl 8A (2003) S24-S28
8. Taskinen M.R. LDL-cholesterol, HDL-cholesterol or triglycerides. which is the culprit?. Diabetes Res Clin Pract 61 Suppl 1 (2003) S19-26
9. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 160-167
10. De Fronzo R., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 171-194
11. Velázquez M.E., Bellabarba G.A., Mendoza S., and Sánchez L. Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin. Fertil Steril 74 (2000) 1159-1163
12. Lo J.C., Feigenbaum S.L., Yang J., Pressman A.R., Selby J.B., and Go A.S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 1357-1363
13. Legro R.S., Kunselman A.R., and Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111 (2001) 607-613
14. Dejager S., Piehard C., Giral P., Brukert E., Federspield M., Beucler., et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol 54 (2001) 455-462
15. Pinwany I.R., Fleming R., Greer I.A., Packard C.J., and Sattar N. Lipids and lipoproteins in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol 54 (2001) 447-453
16. Macut D., Panidis D., Glisic B., Spanos N., Petakov M., Bjekic J., et al. Lipids and lipoproteins profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol 86 (2008) 199-204
17. McLaughlin T., Reaven G., Abbasi F., Lamendola C., Sad M., Waters D., et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am J Cardiol 96 (2005) 399-404
18. Dobiásová M., and Frollich J. The plasma parameter log (TG/HDLC) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 34 (2001) 583-588
19. Mathews D., Hosker J., and Rudenski A. Homeostasis model assessment: insulin resistance and ß cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412
20. Carmina E., and Lobo R.A. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 82 (2004) 661-665
21. Bajares de Lilue M., Pizzi R., and Velázquez Maldonado E. Consenso venezolano de Síndrome de Ovario Poliquístico 2007 (2007), Ateproca, Caracas p. 24-38
22. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome - and new worldwide definition. Lancet 366 (2005) 1059-1062
23. Ford E.S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173 (2004) 307-312
24. Sam S., and Dunaif A. Polycystic ovary syndrome: syndrome XX?. Trends Endocrinol Metab 14 (2003) 365-370
25. Apridonidze T., Essah P., Luorno M., and Nestler J. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1929-1935
26. Ehrmann D., Liljenquist D., Kasza K., Azziz R., Legro R., Ghazzi M.N., and PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 48-53
27. Joan C., Feigenbaum S., Yang J., Pressman A., Selby J., and Go A. Epidemiology and adverse cardiovascular risk profile of diagnostic polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 1357-1363
28. Risto K., and Poyhonen A. Insulin resistance and sympathetic overactivity in women. J Hypertens 24 (2006) 131-141
29. Glueck C., Papanna R., Wang P., Goldenberg N., and Sieve L. Incidence and treatment of metabolic syndrome in newly referred woman with polycystic ovary syndrome. Metabolism 52 (2003) 908-915